July 6, 2021 -- SomaLogic and CM Life Sciences II have released customizable protein panels for pharmaceutical, biotechnology, and academic research purposes.
SomaScan panels include a menu of 7,000 proteins that can be assessed from a single 55-µL plasma or serum sample, according to SomaLogic. They are organized as disease-specific panels or customizable ones, and include the following:
SomaLogic's SomaScan platform identifies new biomarkers and drug targets for the assessment and management of drug therapy responses, the company said. It is currently for research use only.